NO2019039I1 - Denosumab - Google Patents
DenosumabInfo
- Publication number
- NO2019039I1 NO2019039I1 NO2019039C NO2019039C NO2019039I1 NO 2019039 I1 NO2019039 I1 NO 2019039I1 NO 2019039 C NO2019039 C NO 2019039C NO 2019039 C NO2019039 C NO 2019039C NO 2019039 I1 NO2019039 I1 NO 2019039I1
- Authority
- NO
- Norway
- Prior art keywords
- denosumab
- Prior art date
Links
- 229960001251 denosumab Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30117201P | 2001-06-26 | 2001-06-26 | |
| PCT/US2002/020181 WO2003002713A2 (en) | 2001-06-26 | 2002-06-25 | Antibodies to opgl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2019039I1 true NO2019039I1 (no) | 2019-11-05 |
Family
ID=23162250
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20200535A NO345566B1 (no) | 2001-06-26 | 2002-06-25 | OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav |
| NO20041018A NO343687B1 (no) | 2001-06-26 | 2004-03-10 | OPGL bindende antistoff og farmasøytisk sammensetning derav |
| NO20190456A NO344842B1 (no) | 2001-06-26 | 2019-04-04 | OPGL bindende antistoff, polynukleotid sammensetning, vertscelle, farmasøytisk sammensetning samt anvendelse av og fremstilling av antistoffet |
| NO2019039C NO2019039I1 (no) | 2001-06-26 | 2019-11-05 | Denosumab |
| NO2019048C NO2019048I1 (no) | 2001-06-26 | 2019-12-20 | Denosumab |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20200535A NO345566B1 (no) | 2001-06-26 | 2002-06-25 | OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav |
| NO20041018A NO343687B1 (no) | 2001-06-26 | 2004-03-10 | OPGL bindende antistoff og farmasøytisk sammensetning derav |
| NO20190456A NO344842B1 (no) | 2001-06-26 | 2019-04-04 | OPGL bindende antistoff, polynukleotid sammensetning, vertscelle, farmasøytisk sammensetning samt anvendelse av og fremstilling av antistoffet |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2019048C NO2019048I1 (no) | 2001-06-26 | 2019-12-20 | Denosumab |
Country Status (33)
| Country | Link |
|---|---|
| US (8) | US7364736B2 (no) |
| EP (5) | EP2295081B1 (no) |
| JP (13) | JP4212470B2 (no) |
| KR (2) | KR20040023630A (no) |
| CN (2) | CN1547486A (no) |
| AR (1) | AR034637A1 (no) |
| AT (1) | ATE464068T1 (no) |
| AU (2) | AU2002320157C1 (no) |
| BR (1) | BRPI0210579B8 (no) |
| CA (1) | CA2451955C (no) |
| CY (5) | CY1110196T1 (no) |
| DE (2) | DE60235989D1 (no) |
| DK (4) | DK2295081T3 (no) |
| EA (1) | EA021242B9 (no) |
| ES (5) | ES2342820T5 (no) |
| FR (1) | FR10C0050I2 (no) |
| IL (3) | IL159512A0 (no) |
| LU (1) | LU91757I2 (no) |
| ME (2) | MEP32608A (no) |
| MX (1) | MXPA04000134A (no) |
| MY (1) | MY143582A (no) |
| NO (5) | NO345566B1 (no) |
| NZ (4) | NZ530765A (no) |
| PH (2) | PH12012502440A1 (no) |
| PL (1) | PL222211B1 (no) |
| PT (4) | PT2295081T (no) |
| RS (1) | RS54274B1 (no) |
| SG (3) | SG2011076551A (no) |
| TR (3) | TR201809678T4 (no) |
| TW (2) | TWI276443B (no) |
| WO (1) | WO2003002713A2 (no) |
| YU (1) | YU103003A (no) |
| ZA (1) | ZA200400521B (no) |
Families Citing this family (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| CA2274987C (en) * | 1996-12-23 | 2012-01-24 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
| DE69834699T3 (de) * | 1997-04-15 | 2013-11-14 | Daiichi Sankyo Co., Ltd. | Neues protein und verfahren zu dessen herstellung |
| ES2284203T5 (es) * | 1997-04-16 | 2016-03-11 | Amgen Inc. | Proteínas de unión a osteoprotegerina y sus receptores |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| DE69939822D1 (de) | 1998-05-14 | 2008-12-11 | Immunex Corp | Verfahren zur hemmung der wirkung der osteoklasten |
| US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| US8113839B2 (en) | 2000-07-21 | 2012-02-14 | Sony Corporation | Information processing apparatus, information processing method, information processing system, and storage medium |
| WO2002024896A2 (en) | 2000-09-22 | 2002-03-28 | Immunex Corporation | Screening assays for agonists or antagonists of receptor activat or of nf-kb |
| MX337162B (es) | 2001-01-05 | 2016-02-15 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina. |
| NZ530765A (en) * | 2001-06-26 | 2006-11-30 | Amgen Fremont Inc | Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases |
| CA2481074A1 (en) | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
| WO2004024752A1 (ja) | 2002-09-11 | 2004-03-25 | Chugai Seiyaku Kabushiki Kaisha | タンパク質精製方法 |
| EP1479695B1 (en) * | 2003-05-14 | 2010-02-17 | Kenta Biotech AG | Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa |
| JP2007521232A (ja) | 2003-08-08 | 2007-08-02 | アブジェニックス・インコーポレーテッド | 副甲状腺ホルモン（ｐｔｈ）に対する抗体およびその使用 |
| US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| WO2005049649A1 (en) * | 2003-11-05 | 2005-06-02 | Ares Trading S.A. | Process for the purification of il-18 binding protein |
| TWI359026B (en) * | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
| EP2336177A1 (en) | 2004-08-04 | 2011-06-22 | Amgen, Inc | Antibodies to DKK-1 |
| US20060115901A1 (en) * | 2004-10-22 | 2006-06-01 | Bahram Valamehr | Method and media for single cell serum-free culture of CHO cells |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| NZ562949A (en) | 2005-04-11 | 2009-05-31 | Medarex Inc | Protein purification using HCIC and ion exchange chromatography |
| AU2015242973C1 (en) * | 2005-06-14 | 2018-07-05 | Amgen Inc. | Self-buffering protein formulations |
| ES2776657T3 (es) * | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
| EP1909838A2 (en) * | 2005-07-29 | 2008-04-16 | Amgen Inc. | Formulations that inhibit protein aggregation |
| TW200736277A (en) * | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
| WO2007093042A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| WO2007125605A1 (ja) * | 2006-04-28 | 2007-11-08 | Kyoritsu Seiyaku Corporation | 動物由来蛋白なしで培養可能な猫の細胞、これを用いたウイルスの生産方法、及びワクチンの生産方法 |
| PL2061803T5 (pl) | 2006-08-28 | 2023-03-27 | Ares Trading S.A. | Proces oczyszczania białek zawierających fc |
| EP2144613B1 (en) * | 2006-12-29 | 2018-03-21 | OstéoQC Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| UA96473C2 (ru) * | 2007-03-22 | 2011-11-10 | Имклоун Ллк | Жидкая стойкая композиция, которая содержит антитело imc-а12 |
| CN101796072B (zh) * | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| TWI595005B (zh) | 2007-08-21 | 2017-08-11 | 安健股份有限公司 | 人類ｃ－ｆｍｓ抗原結合蛋白質 |
| AU2008298904B2 (en) * | 2007-09-14 | 2014-10-16 | Amgen Inc. | Homogeneous antibody populations |
| ES2750254T3 (es) | 2007-09-27 | 2020-03-25 | Amgen Inc | Formulaciones farmacéuticas |
| EP2206727B1 (en) | 2007-10-11 | 2015-04-01 | Daiichi Sankyo Company, Limited | ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15 |
| EP2219602A1 (en) | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| EP2250251B1 (en) | 2008-01-09 | 2017-11-22 | Sartorius Stedim Cellca GmbH | Improved culture media additive and process for using it |
| CA2714006A1 (en) * | 2008-02-07 | 2009-08-13 | Amgen Inc. | Stabilized protein compositions |
| AR073072A1 (es) | 2008-08-19 | 2010-10-13 | Regeneron Pharma | Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano |
| CA2753332A1 (en) * | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
| WO2010097394A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Multivalent and/or multispecific rankl-binding constructs |
| EP2401298A1 (en) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
| NZ593550A (en) * | 2009-04-09 | 2013-11-29 | Daiichi Sankyo Co Ltd | ANTI-Siglec-15 ANTIBODY |
| MX344382B (es) | 2009-10-23 | 2016-12-14 | Amgen Inc * | Adaptador de vial y sistema. |
| DK4032586T3 (da) | 2010-02-01 | 2025-11-10 | Ferring Microbiome Inc | Bakterieterapi til clostridium difficile-colitis |
| MX2012014180A (es) | 2010-06-07 | 2013-05-06 | Amgen Inc | Dispositivo de administracion de farmacos. |
| JP5699030B2 (ja) * | 2010-07-05 | 2015-04-08 | Ａｘｉｓ株式会社 | エタネルセプトを含む線維筋痛症の治療剤 |
| CN103237813A (zh) | 2010-10-05 | 2013-08-07 | 第一三共株式会社 | 靶向破骨细胞相关蛋白涎免凝集素-15的抗体 |
| EP3517630B1 (en) | 2010-10-06 | 2022-01-19 | Institució Catalana de Recerca i Estudis Avançats | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| EP2691065B1 (en) | 2011-03-31 | 2017-03-01 | Amgen Inc. | Vial adapter and system |
| PL2699293T3 (pl) | 2011-04-20 | 2019-08-30 | Amgen Inc. | Urządzenie do wstrzykiwania automatycznego |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| BR112013030298A2 (pt) | 2011-05-27 | 2017-12-12 | Ablynx Nv | inibição da reabsorção óssea com peptídeos que se ligam ao rankl |
| IL308846B2 (en) | 2011-10-14 | 2025-03-01 | Amgen Inc | Injector and assembly method |
| IN2014CN03555A (no) | 2011-10-25 | 2015-07-03 | Onclave Therapeutics Ltd | |
| US9353153B2 (en) | 2012-02-09 | 2016-05-31 | Riken | Cyclic RNA and protein production method |
| JP6059205B2 (ja) | 2012-03-30 | 2017-01-11 | 第一三共株式会社 | ＣＤＲ改変抗Ｓｉｇｌｅｃ−１５抗体 |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| EP2856159A4 (en) * | 2012-06-01 | 2016-04-13 | Momenta Pharmaceuticals Inc | METHODS RELATING TO DENOSUMAB |
| EP3467124A1 (en) | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| CA2928851A1 (en) | 2012-07-19 | 2014-01-23 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
| KR20150043523A (ko) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | 단백질 불균일성의 제어 방법 |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| TWI698253B (zh) | 2012-09-07 | 2020-07-11 | 美商柯赫勒斯生物科學有限公司 | 阿達木單抗（ａｄａｌｉｍｕｍａｂ）之穩定水性調配物 |
| ES2744244T3 (es) | 2012-10-12 | 2020-02-24 | Inbiomotion Sl | Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| DK3081249T3 (da) | 2012-11-21 | 2021-03-15 | Amgen Inc | Lægemiddeladministrationsanordning |
| DK2948553T3 (da) | 2013-01-25 | 2020-06-29 | Baylor College Medicine | Hjælper-afhængigt afgivelses- og ekspressionssystem til adenoviral genterapi |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| EP3593839A1 (en) | 2013-03-15 | 2020-01-15 | Amgen Inc. | Drug cassette |
| WO2014140933A2 (en) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Method for the prognosis and treatment of cancer metastasis |
| SG11201507417RA (en) | 2013-03-15 | 2015-10-29 | Amgen Inc | Body contour adaptable autoinjector device |
| JP6336564B2 (ja) | 2013-03-15 | 2018-06-06 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入器、および自動注入器システム |
| WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| EP2855533A4 (en) | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | METHODS RELATING TO CTLA4-FC FUSION PROTEINS |
| CN113559363B (zh) | 2013-03-22 | 2023-10-31 | 美国安进公司 | 注射器及装配方法 |
| US10464996B2 (en) | 2013-05-13 | 2019-11-05 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| US9481901B2 (en) | 2013-05-30 | 2016-11-01 | Amgen Inc. | Methods for increasing mannose content of recombinant proteins |
| US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| PT3003330T (pt) | 2013-06-05 | 2018-10-10 | Rebiotix Inc | Terapêutica da restauração da microbiota (trm), composições e processos de fabrico |
| US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| JP6599861B2 (ja) | 2013-08-07 | 2019-10-30 | リグスホスピタレット コペンハーゲン ユニバーシティ ホスピタル | 男性不妊治療用の抗体、化合物、およびその誘導体 |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| WO2015047994A2 (en) * | 2013-09-24 | 2015-04-02 | The Board Of Regentsl Of The University Of Texas System | A novel hormone that promotes bone resorption and uses thereof |
| EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| AU2014333513B2 (en) | 2013-10-09 | 2020-11-26 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer |
| US20160257754A1 (en) | 2013-10-16 | 2016-09-08 | Momenta Pharmaceuticals Inc. | Sialylated glycoproteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| BR112016008946B1 (pt) | 2013-10-24 | 2022-12-27 | Amgen Inc | Injetores e método para montar os injetor |
| CA3168888A1 (en) | 2013-10-24 | 2015-04-30 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
| RU2656153C1 (ru) * | 2013-12-20 | 2018-05-31 | Девелопмент Сентер Фор Байотекнолоджи | Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии |
| CN103965357B (zh) * | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
| WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| HUE048782T2 (hu) | 2014-03-10 | 2020-08-28 | Richter Gedeon Nyrt | Immunoglobulin tisztítása elõtisztítási lépések alkalmazásával |
| FI3834824T3 (fi) | 2014-03-28 | 2025-12-05 | Univ Duke | Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla |
| BR112016025852B1 (pt) | 2014-05-07 | 2022-11-01 | Amgen Inc | Dispositivo de injeção para aplicação de fármaco |
| SG11201609966SA (en) | 2014-06-03 | 2016-12-29 | Amgen Inc | Drug delivery system and method of use |
| HUE042277T2 (hu) * | 2014-06-04 | 2019-06-28 | Amgen Inc | Eljárások fehérjék begyûjtésére emlõssejttenyészetekbõl |
| US10695506B2 (en) | 2014-10-14 | 2020-06-30 | Amgen Inc. | Drug injection device with visual and audio indicators |
| CN107001480B (zh) | 2014-12-11 | 2021-12-03 | 生物运动有限公司 | 用于人c-maf的结合成员 |
| EP3848072A1 (en) | 2014-12-19 | 2021-07-14 | Amgen Inc. | Drug delivery device with proximity sensor |
| EP3233159B1 (en) | 2014-12-19 | 2020-03-04 | Amgen Inc. | Drug delivery device with live button or user interface field |
| ES2748750T3 (es) | 2015-02-17 | 2020-03-17 | Amgen Inc | Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación |
| US10745461B2 (en) | 2015-02-25 | 2020-08-18 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for diet-induced atherosclerosis |
| US10328123B2 (en) | 2015-02-25 | 2019-06-25 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for atherosclerosis |
| US10111928B1 (en) * | 2015-02-25 | 2018-10-30 | Saint Louis University | Pulsed introduction of low-dose RANKL as a therapy for osteogenesis imperfecta |
| EP3261690B1 (en) | 2015-02-27 | 2021-12-15 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
| MX393599B (es) | 2015-04-29 | 2025-03-19 | Radius Pharmaceuticals Inc | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco |
| US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| BR112017026586B1 (pt) | 2015-06-09 | 2021-11-03 | Rebiotix, Inc. | Composições de terapia de restauração de microbiota (mrt) e métodos de fabricação |
| US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| HU231463B1 (hu) | 2015-08-04 | 2024-01-28 | Richter Gedeon Nyrt. | Módszer rekombináns proteinek galaktóz tartalmának növelésére |
| LT3334747T (lt) | 2015-08-13 | 2023-12-27 | Amgen Inc. | Įkrautas giluminis antigeną surišančio baltymo filtravimas |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| EP3386573B1 (en) | 2015-12-09 | 2019-10-02 | Amgen Inc. | Auto-injector with signaling cap |
| WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
| JP6976265B2 (ja) | 2016-03-08 | 2021-12-08 | ヤンセン バイオテツク，インコーポレーテツド | Ｇｉｔｒ抗体、方法、及び使用 |
| EP4035711B1 (en) | 2016-03-15 | 2025-06-04 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
| WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| ES2959783T3 (es) | 2016-05-13 | 2024-02-28 | Amgen Inc | Conjunto de cubierta protectora de vial |
| US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| KR102867720B1 (ko) | 2016-05-25 | 2025-10-01 | 인바이오모션 에스.엘. | c-MAF 상태에 기초한 유방암의 치료 |
| WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| EP3478342B1 (en) | 2016-07-01 | 2025-03-12 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| CA3030862A1 (en) | 2016-07-14 | 2018-01-18 | Scholar Rock, Inc. | Tgfb antibodies, methods, and uses |
| WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
| KR102446838B1 (ko) | 2016-10-21 | 2022-09-26 | 암젠 인크 | 약학적 제형 및 그의 제조 방법 |
| EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR102881465B1 (ko) | 2017-01-05 | 2025-11-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| MX2019008432A (es) | 2017-01-17 | 2019-11-18 | Amgen Inc | Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje. |
| MX2019009625A (es) | 2017-02-17 | 2019-10-09 | Amgen Inc | Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje. |
| MX2019009755A (es) | 2017-02-17 | 2019-10-07 | Amgen Inc | Mecanismo de insercion para dispositivo de suministro de farmacos. |
| JP2020508803A (ja) | 2017-03-06 | 2020-03-26 | アムジエン・インコーポレーテツド | 作動防止特徴部を備える薬物送達デバイス |
| CA3052482A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
| EP3592404A1 (en) | 2017-03-09 | 2020-01-15 | Amgen Inc. | Insertion mechanism for drug delivery device |
| PL3600491T3 (pl) | 2017-03-28 | 2024-03-04 | Amgen Inc. | Układ i sposób montażu trzonu tłoka i strzykawki |
| JOP20190255A1 (ar) | 2017-04-28 | 2019-10-27 | Amgen Inc | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
| CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
| EP3634539A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| WO2018236619A1 (en) | 2017-06-22 | 2018-12-27 | Amgen Inc. | Device activation impact/shock reduction |
| MX2019015479A (es) | 2017-06-23 | 2020-02-20 | Amgen Inc | Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador. |
| IL270784B2 (en) | 2017-07-14 | 2023-11-01 | Amgen Inc | Needle insertion-extraction system with a double torsion spring system |
| EP3655063A1 (en) | 2017-07-21 | 2020-05-27 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
| EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
| JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
| EP3664863A2 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
| WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | BODY INJECTOR WITH STERILE ADHESIVE PATCH |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| US11759565B2 (en) | 2017-10-04 | 2023-09-19 | Amgen Inc. | Flow adapter for drug delivery device |
| IL272636B2 (en) | 2017-10-06 | 2024-10-01 | Amgen Inc | Drug delivery device with interlock assembly and related method of assembly |
| IL273323B2 (en) | 2017-10-09 | 2024-10-01 | Amgen Inc | Drug delivery device with drive assembly and related assembly method |
| IL273582B2 (en) | 2017-11-03 | 2024-12-01 | Amgen Inc | Systems and approaches for sterilizing a drug delivery device |
| WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
| MA50553A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Dispositif d'administration de médicament avec détection de positionnement et de débit |
| SG11202002966QA (en) | 2017-11-10 | 2020-05-28 | Amgen Inc | Plungers for drug delivery devices |
| EP3710089A1 (en) | 2017-11-16 | 2020-09-23 | Amgen Inc. | Autoinjector with stall and end point detection |
| MX2020004996A (es) | 2017-11-16 | 2020-08-27 | Amgen Inc | Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos. |
| KR20200104298A (ko) | 2017-11-22 | 2020-09-03 | 인바이오모션 에스.엘. | c-MAF 상태에 기반한 유방암의 요법 치료 |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| SG11202013177WA (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals Inc | Polymorphic forms of rad 1901-2hcl |
| US12303677B2 (en) | 2018-07-24 | 2025-05-20 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
| US12115360B2 (en) | 2018-07-24 | 2024-10-15 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| MX2021000748A (es) | 2018-07-24 | 2021-03-26 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
| CN112351804A (zh) | 2018-07-24 | 2021-02-09 | 安进公司 | 用于施用药物的输送装置 |
| US12109389B2 (en) | 2018-07-31 | 2024-10-08 | Amgen Inc. | Fluid path assembly for a drug delivery device |
| CA3106452A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
| US12042642B2 (en) | 2018-09-28 | 2024-07-23 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
| CA3110529A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
| TWI824026B (zh) | 2018-10-05 | 2023-12-01 | 美商安進公司 | 具有劑量指示器之藥物遞送裝置 |
| EA202191038A1 (ru) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | Способ платформенной сборки для устройства доставки лекарственного средства |
| IL313960B2 (en) | 2018-10-15 | 2025-10-01 | Amgen Inc | Drug delivery device with a suppression mechanism |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| EP3873563A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| ES3010833T3 (en) | 2018-11-01 | 2025-04-04 | Amgen Inc | Drug delivery devices with partial drug delivery member retraction |
| BR112021008873A8 (pt) | 2018-11-07 | 2023-04-11 | Merck Sharp & Dohme | Formulação |
| HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| KR20210127961A (ko) | 2019-02-12 | 2021-10-25 | 래디어스 파마슈티컬스, 인코포레이티드 | 방법 및 화합물 |
| HU231498B1 (hu) | 2019-04-04 | 2024-05-28 | Richter Gedeon Nyrt | Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával |
| CA3137360A1 (en) | 2019-04-24 | 2020-10-29 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
| JP2022530241A (ja) * | 2019-04-30 | 2022-06-28 | インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス | Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤 |
| JP7608439B2 (ja) | 2019-08-23 | 2025-01-06 | アムジエン・インコーポレーテツド | 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法 |
| WO2021149012A1 (en) | 2020-01-24 | 2021-07-29 | Radius Health, Inc. | Methods of stimulating bone growth with abalopartide and denosumab |
| CN113621060B (zh) * | 2020-05-07 | 2023-07-04 | 浙江瑞硕生物技术有限公司 | 一种opg抗体对及其应用 |
| BR112023024278A2 (pt) | 2021-05-21 | 2024-01-30 | Amgen Inc | Método de otimizar uma receita de enchimento para um recipiente de fármacos |
| EP4590707A1 (en) | 2022-09-23 | 2025-07-30 | The University of North Carolina at Chapel Hill | Methods and compositions for the treatment of melanoma |
| WO2024104409A1 (zh) * | 2022-11-16 | 2024-05-23 | 苏州盛迪亚生物医药有限公司 | 一种含抗rankl-ngf双特异性抗体的药物组合物 |
Family Cites Families (318)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4755465A (en) * | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
| US4710457A (en) | 1983-06-29 | 1987-12-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibody for human hematopoietic glycoproteins and method |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0192658A4 (en) | 1984-07-30 | 1987-07-13 | Salk Inst For Biological Studi | RETROVIRAL GENE TRANSFER VECTORS. |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US5900400A (en) | 1984-12-06 | 1999-05-04 | Amgen Inc. | Serine protease inhibitor analogs |
| US4760130A (en) | 1984-12-06 | 1988-07-26 | Synergen Biologicals, Inc. | Serine protease inhibitors and methods for isolation of same |
| JPS6291197A (ja) | 1985-10-17 | 1987-04-25 | Dainippon Pharmaceut Co Ltd | 抗ヒトインタ−ロイキン１抗体，その製法及びその使用法 |
| US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5359032A (en) | 1987-08-26 | 1994-10-25 | Biogen Inc. | Interkeukin-1 inhibitor |
| IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| US5512544A (en) | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
| IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
| US5319071A (en) | 1987-11-25 | 1994-06-07 | Immunex Corporation | Soluble interleukin-1 receptors |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
| HU222810B1 (hu) | 1988-05-27 | 2003-11-28 | Synergen Inc. | Interleukin-1 inhibitorok, ezeket kódoló DNS-szekvenciák, a szekvenciákat tartalmazó rekombináns DNS-vektorok, a vektort tartalmazó gazdasejtek és rekombináns GT-10-il-1i-2A DNS molekula |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
| US5811261A (en) | 1988-09-12 | 1998-09-22 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
| IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
| EP0364778B1 (en) | 1988-10-01 | 1996-03-13 | Otsuka Pharmaceutical Co., Ltd. | Antibody against interleukin-1beta |
| FR2640146B1 (fr) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2238070T3 (es) | 1989-04-21 | 2005-08-16 | Amgen Inc. | Receptor del tnf, proteina ligante del tnf y adn codante para estos. |
| DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
| ATE119942T1 (de) | 1989-05-18 | 1995-04-15 | Yeda Res & Dev | Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper. |
| IL107267A (en) | 1993-10-12 | 2009-07-20 | Yeda Res & Dev | Ligand to a member of the tnf/ngf receptor family |
| WO1990014363A1 (en) | 1989-05-19 | 1990-11-29 | Amgen Inc. | Metalloproteinase inhibitor |
| US5627262A (en) | 1989-07-05 | 1997-05-06 | The Board Of Regents Of The University Of Oklahoma | Method and composition for the treatment of septic shock |
| IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| CA2485553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | Tumor necrosis factor - .alpha. and - .beta. receptors |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| DK0939121T4 (da) | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
| JPH03127800A (ja) | 1989-10-13 | 1991-05-30 | Teijin Ltd | 腫瘍壊死因子活性抑制物質 |
| DK0502956T3 (da) | 1989-11-29 | 1997-10-20 | Amgen Boulder Inc | Fremstilling af en rekombinant human interleukin-1-inhibitor. |
| ATE128184T1 (de) | 1989-12-13 | 1995-10-15 | Yeda Res & Dev | Expression des rekombinanten tumor-nekrosisfaktor-bindungsproteins i (tbp-i). |
| US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
| AU649245B2 (en) | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| WO1991017184A1 (en) | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
| JPH05506986A (ja) | 1990-05-01 | 1993-10-14 | カイロン コーポレイション | インターロイキン―１拮抗物質及びその利用 |
| US5872095A (en) | 1990-05-01 | 1999-02-16 | Chiron Corporation | IL-1 receptor antagonists medicaments |
| US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| GB2246569A (en) | 1990-06-15 | 1992-02-05 | Charing Cross Sunley Research | Tumour necrosis factor - alpha binding protein |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| ES2120949T4 (es) | 1990-06-28 | 2011-12-29 | Sanofi-Aventis Deutschland Gmbh 50% | Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo. |
| WO1992001002A1 (en) | 1990-07-11 | 1992-01-23 | Teijin Limited | Tumor necrosis factor activity inhibitor and production thereof |
| ATE161720T1 (de) | 1990-08-03 | 1998-01-15 | Smithkline Beecham Corp | Tnf-inhibitoren |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5840496A (en) | 1990-10-09 | 1998-11-24 | Chiron Corporation | Method for diagnosing endometrial cancer |
| GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
| US5858355A (en) | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
| NZ241311A (en) | 1991-01-17 | 1995-03-28 | Gen Hospital Corp | Rna sequence having trans-splicing activity, plant strains |
| WO1992013095A1 (en) | 1991-01-18 | 1992-08-06 | Synergen, Inc. | Methods for treating tumor necrosis factor mediated diseases |
| ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| EP0611302B1 (en) | 1991-10-15 | 2000-03-29 | MULLARKEY, Michael F. | Receptors for treating late phase inflammatory responses |
| WO1993008207A1 (en) | 1991-10-25 | 1993-04-29 | Immunex Corporation | Novel cytokine |
| US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
| ES2038546B1 (es) | 1991-11-08 | 1994-02-16 | Andromaco Lab | Procedimiento de obtencion de un producto de naturaleza polipeptidica con actividad inhibidora de la hiperproduccion del factor de necrosis tumoral. |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| DE69332634T2 (de) | 1992-03-04 | 2003-05-08 | Cell Therapeutics, Inc. | Enantiomere hydroxylierte xanthinverbindungen |
| DE69333027T2 (de) | 1992-03-30 | 2004-05-06 | Immunex Corp., Seattle | Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält |
| CA2118119C (en) | 1992-04-30 | 2001-07-31 | Robert C. Thompson | Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| JPH05312248A (ja) | 1992-05-08 | 1993-11-22 | Nissan Motor Co Ltd | シフトレバー装置 |
| DE4219626A1 (de) | 1992-06-16 | 1993-12-23 | Wehling Peter Priv Doz Dr Med | Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen |
| JPH0630788A (ja) | 1992-07-16 | 1994-02-08 | Otsuka Pharmaceut Co Ltd | ヒトインターロイキン−１に対する組換え抗体 |
| US5545716A (en) | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
| RU2126262C1 (ru) | 1992-09-17 | 1999-02-20 | Амген Боулдер Инк. | Фармацевтическая композиция |
| JPH06111399A (ja) | 1992-09-30 | 1994-04-22 | Sony Corp | 光磁気記録媒体及びその製造方法 |
| US5646154A (en) | 1992-10-07 | 1997-07-08 | Sumitomo Pharmaceuticals Co., Ltd. | Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor |
| CA2146559A1 (en) | 1992-10-23 | 1994-05-11 | Melanie K. Spriggs | Methods of preparing soluble, oligomeric proteins |
| US5891438A (en) | 1992-10-30 | 1999-04-06 | The Regents Of The University Of California | Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination |
| US5866576A (en) | 1992-12-16 | 1999-02-02 | Cell Therapeutics, Inc. | Epoxide-containing compounds |
| ATE174219T1 (de) | 1993-01-08 | 1998-12-15 | Hoechst Ag | Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha |
| ES2159529T5 (es) | 1993-03-05 | 2011-03-09 | Bayer Corporation | Anticuerpos monoclonales humanos anti-tnf alfa. |
| JPH08511507A (ja) | 1993-03-08 | 1996-12-03 | ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 哺乳動物宿主の結合組織を処置するための遺伝子導入 |
| DE69431620T2 (de) | 1993-03-19 | 2003-07-03 | Vacsyn S.A., Paris | Zusammensetzungen für die anwendung in menschlicher therapie, charakterisiert durch die assoziation eines muramylpeptids mit einem cytokin |
| US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
| US5843905A (en) | 1993-06-04 | 1998-12-01 | Vertex Pharmaceuticals, Incorporated | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors |
| FR2706772A1 (en) | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| WO1995004045A1 (en) | 1993-07-28 | 1995-02-09 | Rhone-Poulenc Rorer Limited | Compounds as pde iv and tnf inhibitors |
| AU683114B2 (en) | 1993-11-29 | 1997-10-30 | Merrell Pharmaceuticals Inc. | Novel benzenesulfonylimine derivatives as inhibitors of IL-1 action |
| CA2138305A1 (en) | 1993-12-28 | 1995-06-29 | Naohito Ohashi | Tumor necrosis factor production inhibitors |
| GB9401460D0 (en) | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
| US5608035A (en) | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
| AU1967495A (en) | 1994-02-18 | 1995-09-04 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
| KR100200449B1 (ko) | 1994-03-09 | 1999-06-15 | 디. 제이. 우드, 스피겔 알렌 제이 | Tnf 방출 억제제로서의 이소옥사졸린 화합물 |
| US5741667A (en) | 1994-05-27 | 1998-04-21 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
| US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
| US5817822A (en) | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
| IL114417A0 (en) | 1994-07-07 | 1995-10-31 | Res Dev Foundation | Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use |
| US5877180A (en) | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| DE69519454T2 (de) | 1994-07-14 | 2001-05-03 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen |
| US5641747A (en) | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
| US5633227A (en) | 1994-09-12 | 1997-05-27 | Miles, Inc. | Secretory leukocyte protease inhibitor as an inhibitor of tryptase |
| IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
| CZ288436B6 (en) | 1994-10-05 | 2001-06-13 | Darwin Discovery Ltd | Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised |
| US5852173A (en) | 1994-10-19 | 1998-12-22 | Genetics Institute, Inc. | TNF receptor death ligand proteins and inhibitors of ligand binding |
| TW464656B (en) | 1994-11-15 | 2001-11-21 | Hayashibara Biochem Lab | Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease |
| ZA9510826B (en) | 1994-12-23 | 1996-06-20 | Smithkline Beecham Corp | 3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds |
| JPH10511398A (ja) | 1994-12-23 | 1998-11-04 | スミスクライン・ビーチャム・コーポレイション | ４，４−（二置換）シクロヘキサン−１−カルボキシレート単量体および関連する化合物 |
| US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5886010A (en) | 1995-01-09 | 1999-03-23 | Otsuka Pharmaceutical Company, Limited | TNF-αinhibitor |
| PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
| FI972744A7 (fi) | 1995-02-23 | 1997-08-22 | Novartis Nutrition Ag | Aminohappokokoonpanoja ja niiden käyttö kliinisessä ravinnossa |
| WO1996028546A1 (en) | 1995-03-15 | 1996-09-19 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
| EP0737471A3 (fr) | 1995-04-10 | 2000-12-06 | L'oreal | Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue |
| DK0821671T3 (da) | 1995-04-20 | 2001-04-23 | Pfizer | Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer |
| EP2017337A1 (en) | 1995-04-27 | 2009-01-21 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors |
| EP0824543A1 (en) | 1995-05-10 | 1998-02-25 | Chiroscience Limited | Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use |
| AR004471A1 (es) | 1995-05-31 | 1998-12-16 | Smithkline Beecham Corp | Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| IL122174A (en) | 1995-06-07 | 2004-07-25 | Immunex Corp | Dna encoding a cd40l mutein and a cd40l polypeptide encoded by said dna |
| US5817476A (en) | 1995-06-07 | 1998-10-06 | Genetics Institute, Inc. | Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins |
| US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
| US5830742A (en) | 1995-06-08 | 1998-11-03 | Immunex Corporation | TNF-α converting enzyme |
| EP1666591B1 (en) | 1995-06-29 | 2011-03-23 | Immunex Corporation | Cytokine that induces apoptosis |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| ZA966663B (en) | 1995-08-17 | 1998-02-06 | Genentech Inc | Traf Inhibitors. |
| US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| JPH11511463A (ja) | 1995-08-31 | 1999-10-05 | スミスクライン・ビーチャム・コーポレイション | インターロイキン変換酵素およびアポプトーシス |
| IL115245A (en) | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
| US5968755A (en) | 1995-09-27 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining T-cell profiles of immunocompromised subjects |
| HUP0003760A3 (en) | 1995-10-05 | 2001-05-28 | Darwin Discovery Ltd Cambridge | Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation, process for production thereof and their use |
| DE19540475A1 (de) | 1995-10-20 | 1997-04-24 | Schering Ag | Chirale Methylphenyloxazolidinone |
| CA2237524A1 (en) | 1995-11-14 | 1997-05-22 | Du Pont Pharmaceuticals Company | Novel macrocyclic compounds as metalloprotease inhibitors |
| US6281352B1 (en) | 1995-11-14 | 2001-08-28 | Dupont Pharmaceuticals Company | Macrocyclic compounds as metalloprotease inhibitors |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| CO4750805A1 (es) * | 1995-12-13 | 1999-03-31 | Sumitomo Chemical Co | Compuesto para champu |
| US5869315A (en) | 1995-12-18 | 1999-02-09 | Basf Aktiengesellschaft | Modified interleukin-1β converting enzyme with increased stability |
| US5891883A (en) | 1995-12-21 | 1999-04-06 | Smithkline Beecham Corporation | 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds |
| US5869677A (en) | 1995-12-21 | 1999-02-09 | Smithkline Beecham Corporation | 3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds |
| US5990119A (en) | 1995-12-21 | 1999-11-23 | Smithkline Beecham Corporation | 1,4,4-(trisubstituted)cyclohexane monomers and related compounds |
| US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| CA2238885A1 (en) | 1995-12-29 | 1997-07-10 | Incyte Pharmaceuticals, Inc. | Nucleic acids encoding interferon gamma inducing factor-2 |
| US6046048A (en) | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
| HU230160B1 (hu) | 1996-02-09 | 2015-09-28 | Swedish Orphan Biovitrum Ab (Publ) | Interleukin-I inhibitort és kontrollált felszabadulású polimerként hialuronant tartalmazó készítmények |
| BRPI9707379C8 (pt) | 1996-02-09 | 2017-12-12 | Abbott Biotech Ltd | composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
| US5994351A (en) | 1998-07-27 | 1999-11-30 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| US5981220A (en) | 1996-03-27 | 1999-11-09 | Human Genome Sciences, Inc. | Epidermal differentiation factor |
| GB9607249D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
| GB9607119D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
| GB9607120D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
| US5710013A (en) | 1996-04-19 | 1998-01-20 | Tularik Inc. | Tumor necrosis factor receptor associated factor 6 (TRAF6) |
| GB9609795D0 (en) | 1996-05-10 | 1996-07-17 | Smithkline Beecham Plc | Novel compounds |
| AUPO048296A0 (en) | 1996-06-14 | 1996-07-11 | Fujisawa Pharmaceutical Co., Ltd. | New compound and its preparation |
| US6060283A (en) | 1996-06-27 | 2000-05-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor) |
| EP0818439B1 (en) | 1996-07-02 | 1999-10-13 | Nisshin Flour Milling Co., Ltd. | Imide derivatives |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| US5853977A (en) | 1996-07-12 | 1998-12-29 | Schering Corporation | Mammalian TNF-α convertases |
| JPH10130149A (ja) | 1996-07-12 | 1998-05-19 | Sankyo Co Ltd | Ｔｎｆ産生抑制剤 |
| US5877222A (en) | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
| GB9616643D0 (en) | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
| US5929117A (en) | 1996-08-12 | 1999-07-27 | Celgene Corporation | Immunotherapeutic agents |
| US6069132A (en) | 1996-08-14 | 2000-05-30 | Revanker; Ganapathi R. | Phosphazole compounds |
| US5935977A (en) | 1996-09-25 | 1999-08-10 | Ss Pharmaceutical Co., Ltd. | Substituted vinyl pyridine derivative and drugs containing the same |
| US5962481A (en) | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| GB9621859D0 (en) | 1996-10-21 | 1996-12-11 | Xenova Ltd | Cytokine production inhibitors |
| GB9712761D0 (en) | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
| JPH10147531A (ja) | 1996-11-19 | 1998-06-02 | Otsuka Pharmaceut Co Ltd | ＴＮＦ−α産生抑制剤 |
| US5955480A (en) | 1996-11-20 | 1999-09-21 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
| WO1998021957A1 (en) | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
| US5834435A (en) | 1996-11-27 | 1998-11-10 | Slesarev; Vladimir I. | Inhibition of TNF-α pleiotropic and cytotoxic effects |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| EP0942740B1 (en) | 1996-12-06 | 2003-08-27 | Amgen Inc., | Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
| DK1114864T4 (da) | 1996-12-13 | 2012-09-03 | Schering Corp | Pattedyrcelleoverfladeantigener samt tilhørende reagenser |
| DE19652227A1 (de) | 1996-12-16 | 1998-06-18 | Bosch Gmbh Robert | Verfahren und Vorrichtung zum Zuordnen einer Fernbedienung zu einer Basisstation |
| JPH10231285A (ja) | 1996-12-17 | 1998-09-02 | Ishihara Sangyo Kaisha Ltd | フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物 |
| AU5901598A (en) | 1996-12-20 | 1998-07-17 | Board Of Regents, The University Of Texas System | Compositions and methods of use for osteoclast inhibitory factors |
| CA2274987C (en) | 1996-12-23 | 2012-01-24 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
| US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| PT853083E (pt) | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| ZA9818B (en) | 1997-01-07 | 1998-07-02 | Abbott Lab | C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion |
| US5952320A (en) | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
| US6054559A (en) | 1997-01-28 | 2000-04-25 | Smithkline Beecham Corporation | Interleukin-1 receptor antagonist beta (IL-1raβ) |
| ATE242208T1 (de) | 1997-01-29 | 2003-06-15 | Pfizer | Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität |
| JP3955352B2 (ja) | 1997-02-25 | 2007-08-08 | 株式会社林原生物化学研究所 | 破骨細胞形成阻害剤 |
| US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
| CN1254337A (zh) | 1997-03-04 | 2000-05-24 | 孟山都公司 | N－羟基4－磺酰基丁酰胺化合物 |
| WO1998039326A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| WO1998039316A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
| WO1998039315A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
| WO1998039329A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Amidoaromatic ring sulfonamide hydroxamic acid compounds |
| US6087116A (en) | 1997-03-12 | 2000-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18 (IL-18) receptor polypeptides and their uses |
| US6054487A (en) | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| EP0998300A1 (en) | 1997-03-18 | 2000-05-10 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| JPH10259140A (ja) | 1997-03-18 | 1998-09-29 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生抑制剤 |
| WO1998042325A2 (en) | 1997-03-21 | 1998-10-01 | Cistron Biotechnology, Inc. | INHIBITION OF THE CLEAVAGE OF PRECURSOR IL-1$g(b) |
| GB9706255D0 (en) | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
| US6242615B1 (en) | 1997-03-28 | 2001-06-05 | Zeneca Limited | Process for the preparation of N-(3-hydroxy-succinyl)-amino acid derivatives |
| AU6843298A (en) | 1997-03-28 | 1998-10-22 | Zeneca Limited | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor |
| EA003528B1 (ru) | 1997-04-04 | 2003-06-26 | Пфайзер Продактс Инк. | Производные никотинамида, их применение, фармацевтическая композиция, способ лечения и способ ингибирования изоферментов фдэ4 d |
| AU747385C (en) | 1997-04-10 | 2003-01-30 | Agennix, Inc. | Use of lactoferin in the treatment of allergen induced disorders |
| DE69834699T3 (de) | 1997-04-15 | 2013-11-14 | Daiichi Sankyo Co., Ltd. | Neues protein und verfahren zu dessen herstellung |
| WO1998046757A2 (en) | 1997-04-15 | 1998-10-22 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| ES2284203T5 (es) * | 1997-04-16 | 2016-03-11 | Amgen Inc. | Proteínas de unión a osteoprotegerina y sus receptores |
| FR2762315B1 (fr) | 1997-04-22 | 1999-05-28 | Logeais Labor Jacques | Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha |
| IL132318A0 (en) | 1997-04-24 | 2001-03-19 | Ortho Mcneil Pharm Inc | Substituted imidazoles useful in the treatment of inflammatory diseases |
| CA2229449A1 (en) | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
| FR2762514B1 (fr) | 1997-04-29 | 1999-10-22 | Sanofi Sa | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation |
| JP3776203B2 (ja) | 1997-05-13 | 2006-05-17 | 第一製薬株式会社 | Ｉｃａｍ−１産生阻害剤 |
| BR9809451A (pt) | 1997-05-22 | 2000-06-20 | Searle & Co | Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38. |
| WO1998054201A1 (en) | 1997-05-29 | 1998-12-03 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
| US6265535B1 (en) | 1997-05-30 | 2001-07-24 | The Trustees Of The University Of Pennsylvania | Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses |
| JPH111481A (ja) | 1997-06-10 | 1999-01-06 | Sumitomo Pharmaceut Co Ltd | ピペリジニルフタラジン誘導体 |
| PL199893B1 (pl) | 1997-06-12 | 2008-11-28 | Rhone Poulenc Rorer Ltd | Imidazolilo-cykliczne acetale, kompozycja farmaceutyczna oraz zastosowanie imidazolilo-cyklicznych acetali |
| KR19990001101A (ko) | 1997-06-12 | 1999-01-15 | 손경식 | 캐테콜 아미노산 유도체, 이의 제조방법 및 그를 함유한 약제 조성물 |
| US20020156104A1 (en) | 1997-06-13 | 2002-10-24 | Jerry L. Adams | Novel pyrazole and pyrazoline substituted compounds |
| JPH119269A (ja) | 1997-06-19 | 1999-01-19 | Kaken Pharmaceut Co Ltd | 破骨細胞系細胞 |
| GB9713733D0 (en) | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Poly-branched polycarboxamido compounds |
| GB9713732D0 (en) | 1997-06-27 | 1997-09-03 | Pharmacia & Upjohn Spa | Substituted triazinic compounds |
| GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| AU8757098A (en) | 1997-06-30 | 1999-02-10 | Ortho-Mcneil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| US6235787B1 (en) | 1997-06-30 | 2001-05-22 | Hoffmann-La Roche Inc. | Hydrazine derivatives |
| US6277981B1 (en) | 1997-07-03 | 2001-08-21 | Thomas Jefferson University | Method for design and selection of efficacious antisense oligonucleotides |
| US5843721A (en) | 1997-07-03 | 1998-12-01 | Tularik Inc. | Nucleic acids encoding human NIK protein |
| JP2001500533A (ja) | 1997-07-10 | 2001-01-16 | フアルマシア・エ・アツプジヨン・エツセ・ピー・アー | マトリックスメタロプロテイナーゼ・インヒビター |
| DE19731521A1 (de) | 1997-07-23 | 1999-01-28 | Byk Gulden Lomberg Chem Fab | Budipin bei der Behandlung entzündlicher Erkrankungen des Nervensystems |
| FR2766822B1 (fr) | 1997-07-30 | 2001-02-23 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AR016551A1 (es) | 1997-07-30 | 2001-07-25 | Smithkline Beecham Corp | Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos |
| PT1035848E (pt) | 1997-07-31 | 2003-09-30 | Celgene Corp | Acidos alcano-hidroxamicos substituidos e metodo de reducao dos niveis de tnf alfa |
| WO1999006426A1 (en) | 1997-08-04 | 1999-02-11 | Millennium Biotherapeutics, Inc. | Novel molecules of the tango-77 related protein family and uses thereof |
| EP1003751A1 (en) | 1997-08-04 | 2000-05-31 | Amgen Inc. | Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors |
| CA2268190A1 (en) | 1997-08-06 | 1999-02-18 | Suntory Limited | 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor |
| DK0895988T3 (da) | 1997-08-08 | 2002-09-09 | Pfizer Prod Inc | Arylsulfonylaminohydroxamsyrederivater |
| WO1999007679A1 (en) | 1997-08-08 | 1999-02-18 | Chiroscience Limited | Peptidyl compounds having mmp and tnf inhibitory activity |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| US5994396A (en) | 1997-08-18 | 1999-11-30 | Centaur Pharmaceuticals, Inc. | Furansulfonic acid derivatives and pharmaceutical compositions containing the same |
| CA2300813A1 (en) | 1997-08-21 | 1999-03-04 | Hiroyuki Odaka | Anti-inflammatory agent |
| JPH11139994A (ja) | 1997-10-31 | 1999-05-25 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| JP2001521906A (ja) | 1997-11-03 | 2001-11-13 | ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー | 血管新生を阻害し、癌を処置するための方法及び組成物 |
| US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| WO1999029865A2 (en) | 1997-12-12 | 1999-06-17 | The Rockefeller University | A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof |
| US5998469A (en) | 1998-01-16 | 1999-12-07 | Centaur Pharmaceuticals, Inc. | Thioether furan nitrone compounds |
| DK1049703T3 (da) | 1998-01-20 | 2003-06-02 | Abbott Gmbh & Co Kg | N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2--(4-fluorphenyl)-1,6-dihydro-1-pyrimidinyl)acetoxyl]-L-asparaginsyrealdehyd som en in vivo inhibitor af interleukin-1beta konverterende enzym |
| CA2318030C (en) | 1998-01-23 | 2009-02-17 | Immunex Corporation | Acpl dna and polypeptides |
| WO1999037772A1 (en) | 1998-01-23 | 1999-07-29 | Immunex Corporation | Il-18 receptors |
| AU2472899A (en) | 1998-01-27 | 1999-08-09 | Millennium Pharmaceuticals, Inc. | Novel molecules of the tnf receptor superfamily and uses therefor |
| AU2240299A (en) | 1998-01-27 | 1999-08-09 | American Cyanamid Company | 2,3,4,5-tetrahydro-1h-(1,4)-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors |
| DE69925581T2 (de) | 1998-03-09 | 2006-04-27 | Vertex Pharmaceuticals Inc., Cambridge | 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms |
| US6153591A (en) | 1998-03-16 | 2000-11-28 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
| IL126024A0 (en) | 1998-03-19 | 1999-05-09 | Yeda Res & Dev | Modulators of the function of receptors of the tnf/ngf receptor family and other proteins |
| TR200103406T2 (tr) | 1998-03-19 | 2002-06-21 | Vertex Pharmaceuticals Incorporated | Kaspaz inhibitörleri. |
| CN1181817C (zh) | 1998-03-20 | 2004-12-29 | 第一三得利制药株式会社 | 以苯基甲苯醌为有效成分的NF-kB抑制剂 |
| JPH11266872A (ja) | 1998-03-20 | 1999-10-05 | Suntory Ltd | ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法 |
| CA2325741C (en) | 1998-03-26 | 2007-05-08 | Santen Pharmaceutical Co., Ltd. | Urea derivatives having tnf- .alpha. production inhibitory effects |
| DE69939822D1 (de) | 1998-05-14 | 2008-12-11 | Immunex Corp | Verfahren zur hemmung der wirkung der osteoklasten |
| HUP0102782A3 (en) | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
| HUP0102492A2 (hu) | 1998-06-19 | 2001-11-28 | Smithkline Beecham Corp. | Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására |
| CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| EP1110969A4 (en) | 1998-09-01 | 2002-01-09 | Hayashibara Biochem Lab | INTERLEUKIN 18-BINDING PROTEINS |
| CZ2001789A3 (cs) | 1998-09-15 | 2001-08-15 | Pharmexa A/S | Způsob pro in vivo inhibici aktivity ligandu pro osteoprotegerin |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| CA2356215C (en) * | 1998-12-23 | 2015-11-24 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| CN1309734C (zh) | 1999-02-03 | 2007-04-11 | 安姆根有限公司 | 与免疫应答有关的新颖多肽 |
| AU2880400A (en) | 1999-02-12 | 2000-08-29 | Amgen, Inc. | Tnf-related proteins |
| AUPQ314799A0 (en) | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
| JP2004500063A (ja) | 1999-12-16 | 2004-01-08 | アムジェン インコーポレイテッド | Ｔｎｆｒ／ｏｐｇ様分子およびその使用 |
| AU3695801A (en) | 2000-02-11 | 2001-11-20 | Amgen, Inc. | Receptor from tnf family |
| US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| MXPA02008144A (es) † | 2000-02-23 | 2002-11-29 | Amgen Inc | Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina. |
| AU2001259432B2 (en) | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
| US7102050B1 (en) | 2000-05-04 | 2006-09-05 | Exxonmobil Chemical Patents Inc. | Multiple riser reactor |
| EP1283721A4 (en) * | 2000-05-26 | 2004-07-07 | Smithkline Beecham Corp | ANTI-RANK-LIGAND-BINDING MONOCLONAL ANTIBODIES USEFUL FOR TREATING DISEASES CAUSED BY THE RANK-LIGANDS |
| US7405734B2 (en) * | 2000-07-18 | 2008-07-29 | Silicon Graphics, Inc. | Method and system for presenting three-dimensional computer graphics images using multiple graphics processing units |
| DE10039710B4 (de) | 2000-08-14 | 2017-06-22 | United Monolithic Semiconductors Gmbh | Verfahren zur Herstellung passiver Bauelemente auf einem Halbleitersubstrat |
| US20040247596A1 (en) * | 2000-08-18 | 2004-12-09 | Odgren Paul R. | TRANCE regulation of chondrocyte differentiation |
| JP2004520011A (ja) | 2000-08-21 | 2004-07-08 | スミスクライン・ビーチャム・コーポレイション | Ｒａｎｋリガンド介在障害の治療において有用な抗−ｒａｎｋリガンドモノクローナル抗体 |
| WO2002024896A2 (en) | 2000-09-22 | 2002-03-28 | Immunex Corporation | Screening assays for agonists or antagonists of receptor activat or of nf-kb |
| MX337162B (es) * | 2001-01-05 | 2016-02-15 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina. |
| DE02726901T1 (de) | 2001-05-17 | 2004-07-15 | Immunex Corp., Seattle | Therapeutische verwendung von rang-antagonisten |
| US20030021785A1 (en) | 2001-06-06 | 2003-01-30 | Dougall William C. | Use of rank antagonists to treat cancer |
| NZ530765A (en) | 2001-06-26 | 2006-11-30 | Amgen Fremont Inc | Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases |
| CA2481074A1 (en) † | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
| WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2002
- 2002-06-25 NZ NZ530765A patent/NZ530765A/en not_active IP Right Cessation
- 2002-06-25 JP JP2003509075A patent/JP4212470B2/ja not_active Expired - Lifetime
- 2002-06-25 EP EP10185344.8A patent/EP2295081B1/en not_active Expired - Lifetime
- 2002-06-25 MX MXPA04000134A patent/MXPA04000134A/es active IP Right Grant
- 2002-06-25 SG SG2011076551A patent/SG2011076551A/en unknown
- 2002-06-25 PH PH1/2012/502440A patent/PH12012502440A1/en unknown
- 2002-06-25 PL PL371915A patent/PL222211B1/pl unknown
- 2002-06-25 TR TR2018/09678T patent/TR201809678T4/tr unknown
- 2002-06-25 ME MEP-326/08A patent/MEP32608A/xx unknown
- 2002-06-25 DK DK10185344.8T patent/DK2295081T3/en active
- 2002-06-25 DE DE60235989T patent/DE60235989D1/de not_active Expired - Lifetime
- 2002-06-25 ES ES02749660T patent/ES2342820T5/es not_active Expired - Lifetime
- 2002-06-25 PT PT10185344T patent/PT2295081T/pt unknown
- 2002-06-25 ES ES10185344T patent/ES2706902T3/es not_active Expired - Lifetime
- 2002-06-25 ES ES09156995.4T patent/ES2675735T3/es not_active Expired - Lifetime
- 2002-06-25 PT PT02749660T patent/PT1409016E/pt unknown
- 2002-06-25 NZ NZ547695A patent/NZ547695A/en not_active IP Right Cessation
- 2002-06-25 PT PT91569954T patent/PT2087908T/pt unknown
- 2002-06-25 DK DK09156995.4T patent/DK2087908T3/en active
- 2002-06-25 EP EP09156995.4A patent/EP2087908B1/en not_active Expired - Lifetime
- 2002-06-25 PH PH1/2012/502439A patent/PH12012502439A1/en unknown
- 2002-06-25 EP EP02749660.3A patent/EP1409016B9/en not_active Expired - Lifetime
- 2002-06-25 WO PCT/US2002/020181 patent/WO2003002713A2/en not_active Ceased
- 2002-06-25 DK DK02749660.3T patent/DK1409016T4/da active
- 2002-06-25 AT AT02749660T patent/ATE464068T1/de active
- 2002-06-25 KR KR10-2003-7017009A patent/KR20040023630A/ko not_active Ceased
- 2002-06-25 NZ NZ616594A patent/NZ616594A/en not_active IP Right Cessation
- 2002-06-25 DE DE122010000047C patent/DE122010000047I1/de active Pending
- 2002-06-25 SG SG2005081195A patent/SG173211A1/en unknown
- 2002-06-25 US US10/180,648 patent/US7364736B2/en not_active Expired - Lifetime
- 2002-06-25 YU YU103003A patent/YU103003A/sh unknown
- 2002-06-25 NO NO20200535A patent/NO345566B1/no not_active IP Right Cessation
- 2002-06-25 CA CA2451955A patent/CA2451955C/en not_active Expired - Lifetime
- 2002-06-25 PT PT101813236T patent/PT2270052T/pt unknown
- 2002-06-25 TR TR2018/09008T patent/TR201809008T4/tr unknown
- 2002-06-25 EP EP10181323.6A patent/EP2270052B8/en not_active Expired - Lifetime
- 2002-06-25 AU AU2002320157A patent/AU2002320157C1/en not_active Expired
- 2002-06-25 EA EA200400063A patent/EA021242B9/ru active Protection Beyond IP Right Term
- 2002-06-25 DK DK10181323.6T patent/DK2270052T3/en active
- 2002-06-25 TR TR2019/00581T patent/TR201900581T4/tr unknown
- 2002-06-25 ES ES10181323.6T patent/ES2674888T3/es not_active Expired - Lifetime
- 2002-06-25 CN CNA028166809A patent/CN1547486A/zh active Pending
- 2002-06-25 ME MEP-2008-326A patent/ME00232B/me unknown
- 2002-06-25 IL IL15951202A patent/IL159512A0/xx unknown
- 2002-06-25 CN CN201310052370.5A patent/CN103232539B/zh not_active Expired - Lifetime
- 2002-06-25 ES ES18202340T patent/ES2907826T3/es not_active Expired - Lifetime
- 2002-06-25 KR KR1020107002067A patent/KR101038585B1/ko not_active Expired - Lifetime
- 2002-06-25 RS RS20120347A patent/RS54274B1/sr unknown
- 2002-06-25 SG SG10201603108QA patent/SG10201603108QA/en unknown
- 2002-06-25 EP EP18202340.8A patent/EP3492100B1/en not_active Expired - Lifetime
- 2002-06-25 MY MYPI20022368A patent/MY143582A/en unknown
- 2002-06-25 BR BRPI0210579-9 patent/BRPI0210579B8/pt not_active IP Right Cessation
- 2002-06-26 TW TW091114055A patent/TWI276443B/zh not_active IP Right Cessation
- 2002-06-26 TW TW095103780A patent/TWI326285B/zh not_active IP Right Cessation
- 2002-06-26 AR ARP020102401A patent/AR034637A1/es active IP Right Grant
-
2003
- 2003-12-22 IL IL159512A patent/IL159512A/en active IP Right Grant
-
2004
- 2004-01-23 ZA ZA200400521A patent/ZA200400521B/xx unknown
- 2004-03-10 NO NO20041018A patent/NO343687B1/no not_active IP Right Cessation
-
2005
- 2005-06-25 NZ NZ581637A patent/NZ581637A/en not_active IP Right Cessation
-
2007
- 2007-10-30 US US11/981,664 patent/US8058418B2/en not_active Expired - Lifetime
-
2008
- 2008-07-04 JP JP2008175541A patent/JP4358282B2/ja not_active Expired - Lifetime
- 2008-12-19 AU AU2008261137A patent/AU2008261137C1/en not_active Expired
-
2009
- 2009-07-08 JP JP2009161406A patent/JP4927910B2/ja not_active Expired - Lifetime
-
2010
- 2010-07-08 CY CY20101100637T patent/CY1110196T1/el unknown
- 2010-11-24 LU LU91757C patent/LU91757I2/fr unknown
- 2010-11-24 CY CY2010016C patent/CY2010016I1/el unknown
- 2010-11-25 FR FR10C0050C patent/FR10C0050I2/fr active Active
-
2011
- 2011-11-14 US US13/296,201 patent/US8409578B2/en not_active Expired - Fee Related
-
2012
- 2012-01-17 JP JP2012006740A patent/JP5065529B2/ja not_active Expired - Lifetime
- 2012-03-23 JP JP2012066632A patent/JP2012153701A/ja not_active Withdrawn
- 2012-07-02 JP JP2012148656A patent/JP5576903B2/ja not_active Expired - Lifetime
-
2013
- 2013-03-14 US US13/831,099 patent/US20140134157A1/en not_active Abandoned
-
2014
- 2014-10-19 IL IL235116A patent/IL235116A0/en unknown
- 2014-10-28 JP JP2014218929A patent/JP2015057408A/ja active Pending
- 2014-11-27 JP JP2014239576A patent/JP2015078205A/ja active Pending
-
2015
- 2015-02-12 US US14/621,072 patent/US20150266952A1/en not_active Abandoned
-
2016
- 2016-06-07 JP JP2016113389A patent/JP2016216464A/ja active Pending
- 2016-09-02 US US15/256,194 patent/US20170183417A1/en not_active Abandoned
-
2017
- 2017-12-25 JP JP2017247287A patent/JP2018154614A/ja not_active Ceased
-
2018
- 2018-06-26 CY CY181100655T patent/CY1120656T1/el unknown
- 2018-07-17 CY CY181100747T patent/CY1120658T1/el unknown
-
2019
- 2019-01-21 CY CY20191100079T patent/CY1121151T1/el unknown
- 2019-04-04 NO NO20190456A patent/NO344842B1/no not_active IP Right Cessation
- 2019-06-10 JP JP2019107837A patent/JP2019214563A/ja active Pending
- 2019-11-05 NO NO2019039C patent/NO2019039I1/no unknown
- 2019-12-20 NO NO2019048C patent/NO2019048I1/no unknown
- 2019-12-24 JP JP2019232389A patent/JP2020073518A/ja active Pending
-
2020
- 2020-01-09 US US16/738,751 patent/US20200131271A1/en not_active Abandoned
- 2020-06-18 US US16/905,089 patent/US20200354464A1/en not_active Abandoned
-
2021
- 2021-08-05 JP JP2021128771A patent/JP2022000424A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2019048I1 (no) | Denosumab | |
| DE50204184D1 (de) | Espressobrüheinrichtung | |
| ATE524462T1 (de) | C5-modifizierte indazolylpyrrolotriazine | |
| DE50208022D1 (de) | Wischblatt | |
| DE50212173D1 (de) | sgängern | |
| DE50204386D1 (de) | Kreuztransducer | |
| DE50103741D1 (de) | Welle-Nabe-Verbindung | |
| DE50206021D1 (de) | Schlauchklemme | |
| DE50204551D1 (de) | Kugelgelenk | |
| ATE335486T1 (de) | Hydrazono-malonitrile | |
| DE50211604D1 (de) | Chlag | |
| DE50209410D1 (de) | Kugelgelenk | |
| DE50208372D1 (de) | Schrankaufhängevorrichtung | |
| DE50204794D1 (de) | Kugelgelenk | |
| DE50211290D1 (de) | Handzange | |
| DE50203984D1 (de) | Kugelgelenk | |
| DE50203412D1 (de) | Schwenkkolbenverdränger | |
| DE50208029D1 (de) | Kugelgelenk | |
| ATE355059T1 (de) | Isoxazolopyridinone | |
| DE60129205D1 (de) | Mittelspannungskabelendverschluss | |
| DE50201862D1 (de) | Messwandler | |
| DE50203093D1 (de) | Losradlager | |
| ATA18372001A (de) | Gelenksbolzenbaueinheit | |
| NO20042490D0 (no) | Benzhydrylderivater | |
| ATE319694T1 (de) | Phenylalkyne |